C-terminal GH fragment (research lipolytic analogue)
HGH fragment 176-191
C-terminal fragment of GH studied for adipose lipolysis with less overlap on full GH- growth signalling.
Primary Mechanism of Action
Clinical / Scientific
The 176–191 region of GH has been investigated as a lipolytic domain distinct from the full anabolic GH programme. Evidence is largely preclinical or early clinical; it is not equivalent to labelled somatropin.
Pathway Targets
Lipolytic signalling
Scientific explanation
Experimental adipose effects of the C-terminal fragment.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: Lipolytic signalling
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| Adipocyte lipolysis pathways | Fragment signalling | Fat mobilisation in models | Preclinical |
In Plain Language
This is only the tail end of the growth-hormone chain, studied for fat-burning signals rather than full growth-hormone action.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Lipolytic signalling
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.